Immunity challenge

Rybka, Ted
June 2005
Echo Magazine;6/2/2005, Vol. 16 Issue 19, p53
Interviews Doctor Jon Kaiser about AIDS. Effectiveness of his HIV/AIDS treatment plan; Changes in the development and treatment of HIV and AIDS; Views on the efficiency of the combination of vitamin supplements and antiviral therapy in treating HIV and AIDS.


Related Articles

  • Attitudes to HIV testing in general practice. Kellock, D. J.; Rogstad, K. E. // International Journal of STD & AIDS;May1998, Vol. 9 Issue 5, p263 

    Newer therapies for the treatment of HIV infection and the effectiveness of zidovudine in reducing vertical transmission mean that it is becoming increasingly important to diagnose HIV infection earlier. General practitioners (GPs) attending a local study day on sexually transmitted diseases...

  • Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. Dahab, Mison; Charalambous, Salome; Karstaedt, Alan S.; Fielding, Katherine L.; Hamilton, Robin; La Grange, Lettie; Churchyard, Gavin J.; Grant, Alison D. // BMC Public Health;2010, Vol. 10 Issue 1, p430 

    Background: Many national antiretroviral therapy (ART) programmes encourage providers to identify and address baseline factors associated with poor treatment outcomes, including modifiable adherence-related behaviours, before initiating ART. However, evidence on such predictors is scarce, and...

  • Late presenters to HIV care and treatment, identification of associated risk factors in HIV-1 infected Indian population. Mojumdar, Kamalika; Vajpayee, Madhu; Chauhan, Neeraj K.; Mendiratta, Sanjay // BMC Public Health;2010, Vol. 10 Issue 1, p416 

    Background: Timely access to antiretroviral therapy is a key to controlling HIV infection. Late diagnosis and presentation to care diminish the benefits of antiretrovirals and increase risk of transmission. We aimed to identify late presenters in patients sent for first CD4 T cell count after...

  • "Driving the devil away": qualitative insights into miraculous cures for AIDS in a rural Tanzanian ward. Roura, Maria; Nsigaye, Ray; Nhandi, Benjamin; Wamoyi, Joyce; Busza, Joanna; Urassa, Mark; Todd, Jim; Zaba, Basia // BMC Public Health;2010, Vol. 10 Issue 1, p427 

    Background: The role of religious beliefs in the prevention of HIV and attitudes towards the infected has received considerable attention. However, little research has been conducted on Faith Leaders' (FLs) perceptions of antiretroviral therapy (ART) in the developing world. This...

  • Enfuvirtide Added to an Optimized Antiretroviral Regimen Provided Significant Benefits in Patients with Multidrug-Resistant HIV Infection. Lorber, Bennett // Annals of Internal Medicine;12/7/2004, Vol. 141 Issue 11, p877 

    The article presents information on papers related to infectious diseases in the U.S. The paper "Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America," by J.P. Lalezari, K. Henry, M. O'Hearn et al. studied that enfuvirtide added to an optimized...

  • AIDS Meds Take Center Stage in South Africa. Houlton, Sarah // Pharmaceutical Executive;Sep2003, Vol. 23 Issue 9, p26 

    Reports on the annual spending of South Africa on antiretroviral medicines for AIDS. Provision of drugs by the African government for free; Impact of the AIDS problem on the annual gross domestic product of the country; Availability of the medicines.

  • Review of expert panel recommendations on antiviral treatment.  // AIDS Patient Care & STDs;Dec96, Vol. 10 Issue 6, p378 

    Reports on the new guidelines for antiviral treatment prepared by the 13-member panel appointed by the International AIDS society announced in Vancouver. Treatment for primary infection; Prevention of vertical transmission through therapies.

  • AIDS Drug Assistance Programs: Highlighting Inequities in Human Immunodeficiency Virus- Infection Health Care in the United States. Walensky, Rochelle P.; Paltiel, A. David; Freedberg, Kenneth A. // Clinical Infectious Diseases;9/1/2002, Vol. 35 Issue 5, p606 

    The AIDS Drug Assistance Programs (ADAPs) were founded in 1987 to pay for human immunodeficiency virus (HIV)-related medications in the United States and to help provide prescriptions for HIV-infected patients ineligible for Medicaid who have no private health insurance. As HIV care has shifted...

  • Denying science.  // Nature Medicine;Apr2006, Vol. 12 Issue 4, p369 

    The article comments on the movement of AIDS denialists in spreading conspiracy theories and misinformation to a susceptible public wary of antiretroviral drugs. Scientists have a very important role to play in explaining the science behind AIDS and showing that antiretroviral drugs can...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics